MedTrace Logo

A Study to Describe the Characteristics of Patients Treated With Apremilast for Plaque Psoriasis in Italian Routine Clinical Practice

NCT04031027 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 184

Last updated 2024-03-04

No results posted yet for this study

Summary

The DARWIN study is an Italian multicenter, observational, cross-sectional study involving both a primary data collection (at enrollment visit) and secondary use of data (retrospective observation period). DARWIN will describe patients' characteristics in Italian routine clinical practice as well as the medication utilization patterns, including needs and benefits form the patient's perspective.

Conditions

Interventions

DRUG

Apremilast

Apremilast is prescribed in accordance with the terms of the SmPC and the marketing authorizations.

Sponsors & Collaborators

Principal Investigators

  • MD · Amgen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-07-22
Primary Completion
2021-01-27
Completion
2021-01-27
FDA Drug
Yes

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04031027 on ClinicalTrials.gov